

NEEDS ASSESSEMENT

Recent data have shown that drugs and devices that have been proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfeld J et al J Cardiac Failure 2010;16: 475) are underutilized (Precini et al. Circulation 2008; 118: 926- 933). New therapies for Percutaneous Mechanical Circulatory Support (MCS) have been approved in the last year. Establishing educational initiatives such as this program should help to reduce practice variability, eliminate gaps between guidelines and practice and improve the outcome of patients with heart failure (HF) (Fonarow GF et al Arch Int Med 2005; 165:1469).

As the demand for long-term replacement of diseased hearts increases, there is a clear need for innovative, safe, and durable MCS to treat the growing population of patients with advanced heart failure. (Circulation, 2012:126:2648-2667) In the management of advanced heart failure, the option of long-term MCS as destination therapy (DT), rather than as a temporary bridge to cardiac transplantation, is increasingly being offered to highly selected patients. Recent technological advancements in implantable devices, such as continuous flow systems and smaller pump sizes, have increased the possibility of survival with fewer complications. (Circulation, 2014:7:179-87.) The symposium is designed to educate physicians and provide them with the tools they need to help improve the outcome of their patients.

ACCREDITATION

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

AMA: The University of California San Diego School of Medicine designates this live activity for a maximum of **5.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CULTURAL AND LINGUISTIC COMPETENCY

This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and linguistic competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UCSD CME website at <http://cme.ucsd.edu>.

UC SAN DIEGO SPONSORED EVENT *No Charge for Registration*

LOCATION

BALBOA BAY RESORT
1221 West Coast Highway
Newport Beach, CA 92663
(888) 894-2788

ONLINE REGISTRATION & INFORMATION

Complete Conference Management

3320 Third Avenue, Suite C
San Diego, CA 92103
Email: info@cmmeetings.com

Phone: (619) 299-6673
Fax: (619) 299-6675

Online Registration:
www.cmmeetings.com

University of California, San Diego
9300 Campus Point Drive #7968
La Jolla, CA 92037-7968

THE 2019 SYMPOSIUM ON INNOVATIONS IN HEART RECOVERY THERAPIES Saturday, September 21, 2019

THE 2019 SYMPOSIUM
on

INNOVATIONS IN HEART RECOVERY THERAPIES



SATURDAY
SEPTEMBER 21, 2019

Balboa Bay Resort
Newport Beach, California

Program Director

Eric Adler, MD
UC San Diego Heath
Cardiovascular Institute

Program Co-Directors

Brian Kolski, MD
Orange County Heart Institute

Howie Tran, MD
UC San Diego Heath
Cardiovascular Institute

Sponsored by:

UC San Diego
SCHOOL OF MEDICINE

THE 2019 SYMPOSIUM ON INNOVATIONS IN HEART RECOVERY THERAPIES

SEPTEMBER 21, 2019 BALBOA BAY RESORT NEWPORT BEACH, CA

COURSE DESCRIPTION	PROGRAM	FACULTY
<p>Rapid advances in the diagnosis and treatment of cardiovascular disease in the last five years have radically changed patient care. Novel imaging modalities, pharmaceuticals and devices have improved outcomes for patients with a variety of cardiac conditions. Nonetheless, heart disease remains the number one killer of Americans and heart failure a leading cause of hospitalization.</p> <p>The focus of the Symposium is on the pathophysiology, epidemiology and treatments of cardiovascular disease with a focus on coronary artery disease, valvular disease and heart failure.</p> <p>New therapies based on recent insights into the underlying mechanisms of disease and the use of percutaneous mechanical circulatory support (MCS) will be discussed and their role in the management of patients will be reviewed. Overall, the Symposium will present new and exciting concepts that should be of great value to both providers and their patients.</p> <p><i>This is a UC San Diego sponsored event and registration is free. Online registration is required. Register early - space is limited.</i></p>	<p>8:00-8:50am <i>Registration/Breakfast</i></p> <p>8:50-9:00am Introduction Eric Adler, MD and Brian Kolski, MD</p> <p>9:00-9:30 Contemporary Cardiovascular Screening: How to Identify the Vulnerable Patient Kelly Tucker, MD</p> <p>9:30-10:00 Chronic Total Occlusion Revascularization: Why, When and How Mitul Patel, MD</p> <p>10:00-10:30 Stem Cell and Gene Therapy for Heart Failure Timothy Henry, MD</p> <p>10:30-10:50 <i>Break/Visit Exhibits</i></p> <p>10:50 -11:20 Advances in Cardiogenic Shock Eric Adler, MD</p> <p>11:20-11:50pm Catheter Ablation of Atrial Fibrillation Jay Lee, MD</p> <p>11:50-12:20 Transplant in End-Stage Congenital Heart Disease Marcus Urey, MD</p> <p>12:20-12:50 Rise of the Machines: The Current State of LVAD Care Howie Tran, MD</p> <p>12:50-1:50 <i>Lunch</i></p> <p>1:50-2:20 50 Years of Heart Transplantation Victor Pretorius, MBChB</p> <p>2:20-2:50 Percutaneous Valve Therapies: TAVR, MitraClip and What's Next in Structural Heart Disease Brian Kolski, MD</p> <p>2:50-3:20 Transthyretin Cardiac Amyloidosis: A Not-So-Rare "Rare Disease" Marcus Urey, MD</p> <p>3:20-3:50pm Benefits of Cardiac Rehabilitation Jia Shen, MD</p> <p>3:50 Adjourn</p>	<p>Program Director Eric Adler MD, FACC Professor of Medicine Medical Director, Heart Transplant and MCS Program Division of Cardiovascular Medicine UC San Diego Health Cardiovascular Institute La Jolla, CA</p> <p>Program Co-Directors Brian Kolski, MD Interventional Cardiology Director, Structural Heart Program St. Joseph Hospital, Orange Orange County Heart Institute Orange, CA</p> <p>Howie Tran, MD Assistant Clinical Professor of Medicine Advanced Heart Failure and Transplant Cardiology Division of Cardiovascular Medicine</p> <p>UC San Diego Health Participating Faculty Mitul P. Patel, MD Associate Clinical Professor of Medicine Interventional Cardiology Director of Endovascular Interventions Division of Cardiovascular Medicine</p> <p>Victor Pretorius, MBChB Associate Clinical Professor of Surgery Surgical Director, Heart Transplant and MCS Division of Cardiovascular & Thoracic Surgery</p> <p>Jia Shen, MD Assistant Clinical Professor of Medicine Cardiologist Division of Cardiovascular Medicine</p> <p>Marcus Anthony Urey, MD Assistant Clinical Professor of Medicine Advanced Heart Failure and Transplant Cardiology Division of Cardiovascular Medicine</p> <p>Faculty Timothy D. Henry, MD, FACC, MSCAI Medical Director, The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital The Carl and Edyth Lindner Family Distinguished Chair in Clinical Research Director of Programmatic and Network Development Heart & Vascular Service Line The Christ Hospital Health Network Cincinnati, OH</p> <p>Jay Lee, MD Medical Director, Electrophysiology Hoag Hospital Orange County Heart Institute Orange, CA</p> <p>Kelly Tucker, MD Director, Pacing and Electrophysiology Orange County Heart Institute Orange, CA</p>

LEARNING OBJECTIVES

- At the conclusion of the course, the participant should be able to:
1. Discuss the role of the clinical cardiology in a managed care or capitated health care system
 2. Initiate a diagnosis evaluation in patients with suspected heart failure
 3. Define the anatomic and electro physiologic substrate for supraventricular and ventricular arrhythmias
 4. Describe the clinical pharmacology involved in medical management of heart failure, cardiac arrhythmias and valvular disease
 5. Describe the indications and basic concepts for device therapy in heart failure, including percutaneous and durable ventricular assist devices.
 6. Recognize the indications and basic concepts of the clinical prescription for device therapy in cardiac arrhythmia including permanent pacemakers and implantable cardioverter-defibrillators
 7. Summarize the utility of palliative care in advanced heart failure

TARGET AUDIENCE
This course is designed for all primary care physicians, family medicine, internal medicine and subspecialists including cardiologists and cardiac electrophysiologists.

FACULTY DISCLOSURE It is the policy of the University of California San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity.